Phergain study
Web24. feb 2024 · PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer. The PHERGain II trial will investigate the treatment … PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of treatment and study population.
Phergain study
Did you know?
WebIt is actually the essential chemotherapy in neoadjuvant therapy, the PHERGain study shows that there are patients who can achieve a complete pathological response only with the … WebCochrane Review language. Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language.
WebÉtude PHERGain : étude de phase 2, randomisée évaluant une stratégie thérapeutique adaptée à la réponse au 18F-FDG PET/CT associant le trastuzumab et le pertuzumab chez des patients ayant un cancer du sein HER2 positif. [essai clos aux inclusions] Web1. nov 2024 · In the recently published PHERGAIN study [36], early metabolic response by FDG-PET showed promise to identify patients who will benefit from anti-HER2 therapy and, therefore, can be spared of additional chemotherapy.
WebWith the new study, doctors say that “patients who have tumors of small size, less than 2.5 cm, and the absence of pathological lymph nodes in the axillary, can be treated with the combination of trastuzumab and pertuzumab, now one of the strategies of combination more effective, without chemotherapy “. Two years ago the Phergain-1 study Web10. feb 2024 · Study to improve the life of cancer patients. MEDSIR, a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II …
WebThe PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 ( ClinicalTrials.gov ) View
Web26. máj 2024 · The PHERGain study was carried out in this medical-scientific context. This phase II clinical trial involved researchers from 45 centres in seven European countries, … diy halloween witch broomWebTrastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study. Jules Bordet Institute Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study. craigslist oshawa ontarioWeb14. jún 2010 · Most Common Grade 3 and Worse Adverse Events in the Overall Study Period. eTable 5. Most Common Serious Adverse Events in the Overall Study Period ... diy halloween trick or treat bags for kidsWeb19. máj 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary … craigslist oshkosh wiWeb1. máj 2024 · In the recently published PHERGAIN study [36], early metabolic response by FDG-PET showed promise to identify patients who will benefit from anti-HER2 therapy … craigslist oshawa furnitureWeb27. okt 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 … craigslist oshkosh wisconsinWeb2024-10-29. due-trials. Not reported Terminated. 2024-004324-30. A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progressi... 2024-03-31. due-trials. Reported results. craigslist oshkosh area